No More $35 Insulin Cap? Eli Lilly, Plaintiffs Call Off $13.5M Class Action Settlement

An unfavorable ruling by a judge has scuttled an agreement in which Eli Lilly would have capped insulin prices and paid $13.5 million to resolve claims that it had inflated the drug’s cost.

Lawyers for a proposed nationwide class of individuals, who paid for Lilly’s Humalog injection and other insulin drugs, said in a filing in Newark, N.J. federal court that they and Lilly had decided not to go forward seeking approval for the deal.

One lawyer, Steve Berman, told Reuters that the decision to drop the deal came after U.S. District Judge Brian Martinotti in February refused to certify a class in the litigation, which also targets insulin drug makers Novo Nordisk and Sanofi. The plaintiffs since have filed an amended version of their complaint, again seeking to proceed as a class action. Berman called the demise of the settlement, which would have capped patients’ out-of-pocket insulin costs at $35 per month for four years, a “potentially big loss for consumers.”

Lilly said in a statement that the plaintiffs’ claims lacked merit and that it would continue to defend itself. Lilly and the other companies still face lawsuits by several states, some of which objected to the settlement because it could interfere with their own litigation. The company in February settled with Minnesota, agreeing to cap prices and donate insulin to clinics in the state.

Plaintiffs in the cases allege that insulin manufacturers set artificially high list prices for their products, while paying rebates to pharmacy benefit managers in exchange for their covering the drug on behalf of health plans. Lilly said last March that it would slash insulin prices and make it available to many patients for $25 or $35, following pressure from the Biden administration, lawmakers and advocacy groups over skyrocketing costs.

A survey released last year by Sen. Elizabeth Warren, D-Mass., found that many patients nevertheless are still were being charged hundreds of dollars for treatments. Around 8.4 million of the 37 million people in the United States with diabetes use insulin, according to the American Diabetes Association.

 

Source Link

Recommended Articles

New NFIB Survey: Small Businesses Report Reduced Optimism

The NFIB Small Business Optimism Index fell 0.6 points in May to 95.3, remaining below its 52-year average of 98.0. The Uncertainty Index rose 3 points from April to 91, remaining well above its historical average of 68. As reported in NFIB’s monthly Jobs Report, the NFIB Small Business Employment Index remained essentially flat, registering 100.3 in May. ...

Read More

Trump Announces TrumpRx Expansion, Adding 160 More Drugs

President Trump on Friday announced that over 100 prescription medications would be added to his administration’s direct-to-consumer drug platform, TrumpRx, the second expansion of the initiative in as many months. “I am pleased to announce that TrumpRx.gov is adding another 160 Prescription Drugs, at highly discounted prices, for a new total of over 800 of the most commonly-used Prescription Drugs,” ...

Read More

Skyrocketing GLP-1 Demand Creates Major Financial Strain For Employers

GLP-1 drugs are a double-edged sword for the nation’s employers. Although they are having a demonstrable effect on workplace health, the high cost is putting a strain on their budgets. GLP-1s, known by brand names such as Ozempic, Wegovy, Mounjaro or Zepbound, originally were developed to help regulate blood sugar in people with Type 2 ...

Read More

Judge Throws Out Policy Imposing $100,000 Fees for Skilled Worker Visas

A Trump administration initiative to impose $100,000 fees on employers seeking visas for skilled foreign workers amounts to an unlawful tax on those companies and must be voided “in its entirety,” a federal judge ruled on Monday. The decision by Judge Leo T. Sorokin of the Federal District Court for the District of Massachusetts nullified ...

Read More
arrowcaret-downclosefacebook-squarehamburgerinstagram-squarelinkedin-squarepauseplaytwitter-squareyoutube-square